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1. Abstract 
Despite some notable successes cancer remains, for the most part, a seemingly intractable 
problem. There is, however, a growing appreciation that targeting the tumor epithelium in 
isolation is not sufficient as there is an intricate mutually sustaining synergy between the tumor 
epithelial cells and their surrounding stroma. As the details of this dialogue emerge, new 
therapeutic targets have been proposed. The FDA has already approved drugs targeting 
microenvironmental components such as VEGF and aromatase and many more agents are in the 
pipeline. In this article, we describe some of the “druggable” targets and processes within the 
tumor microenvironment and review the approaches being taken to disrupt these interactions.  
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2. Introduction 
Cancer was long viewed as a cell-autonomous process, in which successive acquisition of 
mutations in oncogenes and tumor suppressor genes resulted in progressively enhanced 
proliferation and resistance to cell death. This is now widely viewed as an oversimplification and 
the recognition that additional cell types and the soluble factors they produce make a vital 
contribution to epithelial tumorigenesis.  
Carcinomas are complex organs (1) consisting of tumor epithelial cells, in a 
microenvironment rich in multiple non-malignant, albeit altered, cell types – fibroblasts, 
endothelial cells and leukocytes – all of which interact, either physically or via the secretion of 
paracrine signaling molecules. In this respect, the tumor organ is no different from all of the 
other organs, the form and function of which are the product of an exquisite dialogue between 
the epithelial and stromal cells, and an understanding of the processes driving its biogenesis 
should prove to be the making of its undoing.  
While this paradigm shift has caused a fundamental reevaluation of how cancer biologists 
think about tumorigenesis, it is really “old news” for developmental biologists who, for almost a 
century, have realized that cues from adjacent cell types can induce important changes in cell 
fate during development. Here, the intricate cross-talk of soluble factors between epithelial and 
mesenchymal cells plays a vital role in tissue morphogenesis and function. This field was first 
illuminated by the work of Spemann and Mangold in salamanders (2), which showed that 
ectopically engrafted tissue could modulate the differentiation of adjacent structures. Later, co-
culture experiments were used to define some of the reciprocal interactions between epithelium 
and stroma which are necessary for the induction of the differentiated state (3, 4), and these 
principles have been shown to hold true in many organs, including the mammary gland, kidney 
and prostate (for reviews see 5, 6, 7).  
A broad appreciation of the importance of heterotypic cell-cell interactions in tumor 
induction and progression lagged considerably behind, despite the intermittent publication of 
compelling papers on this subject. The demonstration by Judah Folkman (8) that tumors had the 
power to stimulate the growth of new blood vessels provided further convincing evidence that 
tumorigenesis could not proceed without active cooperation from non-malignant cells. DeCosse 
and coworkers showed that a mammary tumor could be induced to differentiate by co-culture 
with normal mammary stroma (9). Leland Chung and his colleagues showed that co-injection of 
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either normal or transformed fibroblasts could enhance the tumorigenicity of several different 
human cancer cell lines in xenograft experiments (10). Similarly, Cunha and co-workers showed 
that fibroblasts from reactive stromal regions of tumors had the capacity to transform otherwise 
non-malignant prostate epithelial cells (7, 11). More recently, evidence is emerging that 
mutations in proto-oncogenes and tumor suppressor genes (12) as well as distinctive epigenetic 
changes (13) are not always restricted to the tumor epithelium and that clones of altered stromal 
cells been observed further supports the contention that tumor-stromal co-evolution can be an 
important driver of tumorigenesis. 
It is also clear that only a proportion of familial cancers are explained by the inheritance 
of strongly predisposing mutant alleles, such as BRCA1, BRCA2 and APC. A significant 
fraction of the remaining familial component is likely to arise from the contribution of lower 
penetrance alleles which, while having weak effects alone, may lower the threshold at which 
tumorigenesis is likely to occur. Interestingly, SNPs altering the expression level or activity of a 
number of microenvironmental proteins have been reported to predispose to cancer (reviewed in 
14). 
Following up from Beatrice Mintz’s demonstration that transformed embryonal 
carcinoma cells injected into blastocysts could contributed to tumor-free tissues in adult mice 
(15), work in the 1980’s from our laboratory showed that expression of the viral Src oncogene 
did not result in cellular transformation in the developing chick embryo, yet dissociated cells 
were demonstrably transformed in culture. These studies led to the realization that even 
expression of a potent oncogene was not sufficient for transformation and that additional factors, 
such as disruption of tissue architecture by wounding, may be necessary (16, 17). These studies 
were consistent with the ideas of Dvorak on the similarities between tumors and wounds (18) 
and also the growing appreciation of the relationships between inflammation and tumorigenesis 
(see below). In the chick model, TGF-beta was implicated as a key mediator in this process (19) 
a finding which conflicted with the then dominant theory of TGF-beta as a proliferation 
suppressor; subsequent studies established that disruption of the microenvironment by excessive 
production of matrix metalloproteinases (MMPs) can lead to genomic instability, epithelial-to-
mesenchymal transition and malignant transformation of mammalian cells in vitro and in vivo 
(20-22).  
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Collectively, these studies established that heterotypic cell-cell interactions were critical 
to tumor induction and progression, but the identity of many of the molecular mediators of this 
communication remained to be determined. In the past few years, considerable progress has been 
made toward identifying some of the key signaling processes which underlie epithelial-stromal 
interactions. This newfound understanding has opened the way to the design of rational therapies 
which target the microenvironment of the tumor, as a means of destroying the tumor itself. 
 
3. Heterotypic cell signaling mediators 
The extent to which soluble factors which are secreted by one cell type and act by 
binding receptors on other cell types influence the malignant process is now widely appreciated. 
This has provided a profusion of therapeutic leads, some of which are already approved drugs 
and many more of which are in the pipeline. One example of a signaling molecule targeted in 
this way is tumor necrosis factor alpha (TNF-alpha) which, although originally believed to have 
predominantly anti-tumor activity, has more recently been shown to exert many pro-tumorigenic 
functions (23). One approach has led to the generation of an anti-TNF-alpha monoclonal 
antibody, Infliximab, which is approved in the US for the treatment of Crohn disease and 
ulcerative colitis, both of which predispose to colorectal cancer. An alternative strategy, to build 
a decoy receptor which will sequester soluble TNF-alpha is marketed as Etanercept and is 
approved for the treatment of rheumatoid arthritis. Monoclonal antibodies against TNF-alpha 
have shown efficacy in a series of preclinical models (23) and both of these drugs are in clinical 
trials to test efficacy in cancer. This paradigm of using decoy receptors and blocking antibodies 
is a recurrent theme in microenvironment-directed therapies.  
Cells of the immune system have long been observed in association with tumors (24). 
This was thought to reflect the body’s response to the tumor organ, but several studies have now 
shown that such lymphocytic infiltrates actually correlate with poor prognosis (25). Tumor cells 
secrete a series of chemokines which actively promote macrophage recruitment (26, 27). Pollard 
and co-workers have delineated an important feedback loop by which tumors recruit cells of the 
immune system, which then provide the tumors with mitogenic stimuli. CSF1, produced by 
tumor cells is a potent chemoattractant for macrophages. Macrophages are rich in growth factors, 
such as EGF, and proteases, which can promote tumor cell proliferation, angiogenesis and matrix 
remodeling, all of which can facilitate progression (28). Treatments which have shown promise 
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against tumor-associated macrophages include Trabectedin (29) and a blocking antibody against 
CSF1 which has shown significant efficacy in a breast cancer xenograft model (30). 
Instead of targeting macrophages, another exciting approach has been the proposal to use 
macrophages (or, more likely their monocyte precursors) as vehicles for gene therapy (27). This 
builds on the approach pioneered by Rosenberg of gene transfer into tumor infiltrating 
lymphocytes (31). Because they accumulate preferentially in hypoxic areas of tumors, 
macrophages may prove an effective means of drug delivery to regions of the tumor which are 
difficult to target by other means and which are believed to contain cells which are more resistant 
to chemotherapies. As proof of principle, it was shown that macrophages transduced with 
CYP2B6 could infiltrate tumor spheroids grown in vitro and activate cyclophosphamide, 
resulting in death of adjacent tumor cells (32). Similarly, Dubinett, Sharma and colleagues 
demonstrated that introducing dendritic cells transduced with CCL21 into the tumor 
microenvironment in a transgenic mouse model of broncheoalveolar cell carcinoma results in the 
recruitment of many endogenous dendritic cells, T-lymphocytes and natural killer cells, which 
significantly extended the survival of the mice (33). Vinel and co-workers have shown efficacy 
of fibroblasts transduced with IL-12 in mouse models of pancreatic and hepatocellular carcinoma 
(34, 35).  
Transforming growth factor beta (TGF-beta) has complex autocrine and paracrine roles 
in tumor progression. This factor is a potent inhibitor of epithelial cell growth, but sensitivity to 
these effects of TGF-beta is frequently lost during tumor progression and, in later stages, TGF-
beta signaling has pro-oncogenic functions which is reflected by the poor prognosis of tumors of 
many tissues which overexpress TGF-beta (36). Compelling evidence for a role of this pathway 
in stromal-epithelial crosstalk emerged from the work of Moses and colleagues, who showed that 
deletion of the TGF-beta type II receptor in stromal fibroblasts resulted in the transformation of 
adjacent epithelia in the prostate and forestomach (37). Fibroblasts from these animals have 
upregulated expression of growth factors and increased the proliferation of mammary cancer 
cells when co-injected beneath the kidney capsule (38).  Existing strategies to target this pathway 
include small molecule inhibitors of the receptors, and antibodies and decoy receptors which 
prevent ligand-receptor interactions (39). 
 
4. Nonsteroidal anti-inflammatory drugs (NSAIDs) 
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As many as 1 in 6 epithelial cancers are believed to arise at sites of inflammation (40, 41), 
suggesting that the disruption of tissue architecture, the influx of immune cells and the tissue 
repair processes might allow pre-existing neoplastic cells to escape the constraints imposed on 
them by their microenvironment. Large observational studies of hundreds of thousands of 
individuals have associated frequent aspirin use with a significantly reduced incidence of 
colorectal cancer (42, 43), and evidence is also increasing that NSAID use may help in the 
chemoprevention of cancers of the breast, ovary, prostate and lung (44, and references therin). 
NSAIDs suppress the activity of the cyclooxygenases, COX1 and COX2, the latter being the 
primary inducible form which produces prostaglandins in inflammation and in tumors. 
Prostaglandins activate a diverse array of signaling pathways with pro-tumorigenic roles (45). 
  
5. Angiogenesis inhibitors 
The recruitment of a vasculature to supply blood and oxygen is an essential transition 
which must occur if a tumor is to grow larger than a couple of mm3, which is the diffusion limit 
for oxygen in vivo. Angiogenesis is regulated by a delicate balance between a series of pro- and 
anti-angiogenic factors. Because the vasculature is genomically stable, it was hypothesized that 
targeting this key aspect of the malignant phenotype might prove effective therapeutically while 
having less risk of developing somatically acquired resistance. Several angiogenesis inhibitors 
are in development and some have already been approved. Bevacizumab (AvastinTM), a 
humanized monoclonal anti-VEGF antibody has been approved in combination with 5-
Fluorouracil for the treatment of metastatic colorectal cancer (46), and following this validation 
many other anti-VEGF agents are at various stages of development (47). The arsenal of anti-
angiogenic drugs has been further expanded following the realization that the receptor tyrosine 
kinases which are activated by these ligands are also inhibited by existing drugs. BAY 43-9006, 
a Raf inhibitor, also potently inhibits VEGFR2 and VEGFR3 (48). Gleevec, which is approved 
for inhibition of cKIT in gastrointestinal stromal tumors and BCR-ABL in chronic myelogenous 
leukemia, is also a potent inhibitor of the PDGF Receptor (49). Targeting PDGFR on pericytes, 
with consequent disruption of the tumor vasculature, may prove an unforeseen bonus of using 
Gleevec, and may indeed contribute to its effectiveness in vivo. In some cases, it seems, the “off-
target” effects of a drug might be beneficial! 
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The new interest in angiogenesis has led also to the rehabilitation of an older drug, 
Thalidomide, which was removed from sale in 1962 when it was realized it caused birth defects 
in children. Thalidomide is a potent inhibitor of angiogenesis (50), and clinical efficacy has been 
demonstrated in multiple myeloma (51). In 2005 it was approved in Australia for the treatment of 
this disease, and the US FDA followed suit in 2006. 
As our understanding of the role of the extracellular matrix in the maintenance of tissue 
homeostasis has improved, it has been realized that many extracellular matrix proteins possess 
cryptic fragments which, when released by cleavage, can exert potent biological effects. 
Examples of such fragments include Canstatin and Tumstatin (from Collagen IV), endostatin 
(from Collagen XVIII), Angiostatin (from plasminogen) and Restin (from Collagen XV), all of 
which exert antiangiogenic effects (52). Intriguingly, Collagen XVIII, from which Endostatin is 
derived, is located on Chromosome 21, the chromosome of which three copies are found in 
individuals with Down syndrome. When controlled for age, individuals with Down syndrome 
develop epithelial cancers at one tenth of the rate of unaffected individuals (53). Transgenic mice 
engineered to overexpress endostatin experience a significant reduction in the rate of tumor 
growth (54). In clinical trials (55, 56), recombinant human endostatin failed to live up to the 
dramatic promise it showed in earlier pre-clinical studies (57), however a new more soluble 
variant called Endostar (58) was approved in China in 2005 (59) and we eagerly await the further 
evaluation of this peptide in additional studies. 
 
6. Aromatase inhibitors 
For ERα-positive breast cancers, estrogen provides a crucial mitogenic cue and estrogen 
receptor antagonists, such as tamoxifen, have had a very significant impact in the clinic. 
Estradiol is synthesized in the ovaries and at extragonadal sites, with extragonadal synthesis 
being dominant after the menopause. In postmenopausal women with estrogen-dependent breast 
cancer, estrogen produced locally within the breast stromal fibroblasts and adipocytes is the 
primary source of this factor (60, 61). Aromatase in these cells is a key enzyme in estradiol 
biosynthesis and so represents an excellent target for microenvironment targeted therapy. This is 
a clear example of a crucial growth factor being synthesized in the breast tumor 
microenvironment by a “druggable” target. The third-generation aromatase inhibitors – 
anastrazole, letrozole and exemesthane – can inhibit whole body aromatization by up to 98%. 
 8
Kenny et al. Targeting the tumor microenvironment 
The aromatase inhibitors have been shown to be even more effective than tamoxifen at 
preventing breast cancer recurrence in post-menopausal women (62). This remains, to our 
knowledge, the most successful example yet of a therapy targeted at a component in the 
microenvironment resulting in strong efficacy against tumors in a clinical setting. 
 
7. Bisphosphonates 
More than a century ago, Paget observed that tumors of different tissues exhibited an 
apparent preference in the distant sites at which metastases were established, likening tumor cells 
to seeds which could only flourish if they fall on a congenial soil (63). Metastasis to bone is a 
frequent event in advanced cancer, leading to pain, a loss of bone mineral density and an 
increased susceptibility to fractures. The microenvironment of the bone is particularly hospitable 
to the cells of prostate, breast and renal tumors and multiple myeloma, all of which can adapt 
very well to this niche. Bisphosphonates, such as Zoledronic Acid, Ibandronate, Pamidronate and 
Clodronate, achieve high local concentrations by binding to bone hydroxyapatite, leading to loss 
of osteoclasts and, consequently, an attenuation of bone resorption. These pyrophosphate analogs 
are effective inhibitors of the mevalonate pathway resulting in a defect in the prenylation of 
signaling proteins, leading to osteoclast apoptosis. Inhibition of the same pathway by Zoledronic 
Acid in tumor cells might also elicit direct anti-tumor effects (64).  
Zoledronic acid has shown considerable promise in the treatment of tumors metastasizing 
to bone (reviewed in 65). For example, if treatment is started when bone loss due to multiple 
myeloma is first detected, this significantly reduces the incidence and delays the time of onset of 
skeletal complications. Preliminary data from a number of trials using bisphosphonates less 
potent than Zoledronic Acid (reviewed in 66) suggest that this treatment may also prevent breast 
cancer metastasis to bone. A number of trials are now underway to test the more potent 
compound in the adjuvant setting.  
 
8. Conclusions 
We are now coming to the appreciation that the complexities of cancer will rarely be 
solved by single agents and that rational combinations of targeted therapies chosen on the basis 
of the particular lesions in individual tumors will be necessary. The scientific arguments for this 
are clear and the moral arguments are compelling. It is frustrating, however, that the financial 
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interests of pharmaceutical companies are often at odds with the interests of patients, and that the 
legal and regulatory barriers to testing combinations of patented drugs in large trials are 
depressingly prohibitive (67). Nevertheless, we remain greatly encouraged that so many 
colleagues now appreciate the importance of targeting the tumor microenvironment and, as our 
collective understanding of the complexities of tumor ecology deepens, we hope that patients 
will soon benefit from drug combinations targeting the whole tumor organ and not just its 
epithelial component. 
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Table 1 Microenvironmental processes targeted by existing and developing treatments 
Microenvironmental target Therapeutic agent 
Estrogen biosynthesis Aromatase inhibitors (anastrozole, letrozole and exemesthane) 
  
Macrophage-Tumor interactions Anti-CSF1 monoclonal antibody 
 Trabectedin 
  
Prostaglandin production Cox2 inhibitors (e.g. Non-steroidal anti-inflammatory drugs) 
  
Metastatic microenvironment in bone Osteoclast targeting agents (e.g. zoledronic acid, clodronate) 
  
Stromal-epithelial interaction TGF-beta inhibitors (e.g. SB-431542, LY580276, Lerdelimumab) 
 TNF-alpha inhibitors (e.g. Etanercept, Infliximab) 
  
Angiogenesis Anti-VEGF monoclonal antibody (Bevacizumab) 
 VEGF Receptor inhibitors (e.g. BAY-43-9006) 
 PDGF Receptor inhibitor (e.g. Gleevec) 
 Pro-angiogenic integrins inhibitors (e.g. endostatin and other ECM fragments) 
 Thalidomide (several possible mechanisms) 
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Abbreviations: CSF: Colony stimulating factor, NSAID: Non-steroidal anti-inflammatory drug, 
PDGF: Platelet derived growth factor, SNP: Single nucleotide polymorphism, TGF: 
Transforming growth factor, TNF: Tumor Necrosis Factor, VEGF: Vascular endothelial growth 
factor 
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